Board Meeting1 Sept 2026, 05:10 pm
Gujarat Themis Biosyn Plans ₹335 Cr Preferential Issue
AI Summary
Gujarat Themis Biosyn Limited announced its board has approved a preferential issue of up to 82,10,786 equity shares at ₹408 per share, aggregating up to ₹335 crore. The issue includes a securities premium of ₹407 per share. The funds will be raised via private placement from five proposed allottees, including promoter group entity Pharmaceutical Business Group (India) Limited. The approval is subject to necessary regulatory and shareholder consents.
Key Highlights
- Board approved preferential issue of equity shares.
- Issue size up to ₹335 crore at ₹408 per share.
- Funds to be raised via private placement.
- Includes promoter group and other investors.
- Subject to shareholder and regulatory approvals.
Price Impact
More from GUJTHEM